Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis
- PMID: 34454401
- PMCID: PMC8387202
- DOI: 10.1016/j.ebiom.2021.103567
Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis
Conflict of interest statement
Declaration of Competing Interest All authors have no conflicts of interest to disclose.
References
-
- Dikow R., Eckerle I., Ksol-Rudek D., Hampel H., Schwenger V., Zeier M. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis. 2011;57(5):716–723. doi: 10.1053/j.ajkd.2010.11.031. MayEpub 2011 Feb 23. PMID: 21349617. - DOI - PubMed
-
- Stumpf J., Siepmann T., Lindner T., Karger C., Schwobel A.L. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet. 2021 doi: 10.1016/j.lanepe.2021.100178. July 22. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
